Treatment Groups | IL-1β | IL-4 | IL-6 | IL-12 (p40/p70) | IL-17 | KC | MIG | MIP-1α | VEGF |
---|---|---|---|---|---|---|---|---|---|
0%FS | 26.7 ± 8.3 | 28.6 ± 6.3 | 21.0 ± 5.9 | 19.2 ± 3.1 | 0.6 ± 0.2 | 658.6 ± 39.3 | 15.3 ± 2.5 | 25.4 ± 7.8 | 26.6 ± 4.6 |
0%FS + XRT | 12.1 ± 2.7 | 17.4 ± 1.0 | 66.0 ± 42.5 | 88.1 ± 18.2 | 0.4 ± 0.1 | 173.0 ± 47.0 | 11.4 ± 4.2 | 18.5 ± 3.7 | 43.9 ± 4.5 |
10%FS | 14.4 ± 5.1 | 20.4 ± 2.3 | 16.6 ± 2.0 | 12.9 ± 1.3 | 0.4 ± 0.1 | 730.7 ± 58.4 | 14.6 ± 4.4 | 16.5 ± 3.0 | 21.1 ± 2.9# |
10%FS + XRT (0 Day) | 12.4 ± 0.8 | 18.2 ± 0.3 | 20.4 ± 1.1$ | 51.1 ± 13.3$ | 0.6 ± 0.1 | 521.0 ± 165.0* | 20.9 ± 4.9 | 13.3 ± 1.5 | 21.4 ± 3.8# |
10%FS + XRT (-3 wks) | 14.7 ± 1.5 | 17.9 ± 0.6 | 28.0 ± 6.4 | 54.2 ± 13.6* | 0.9 ± 0.3* | 396.0 ± 49.3 | 14.8 ± 2.8 | 15.7 ± 1.6 | 16.9 ± 3.4# |
10%FS + XRT (+2 wks) | 13.1 ± 2.9 | 15.9 ± 1.0 | 16.6 ± 1.7* | 43.2 ± 7.9* | 0.3 ± 0.1§§ | 380.5 ± 162.7 | 7.2 ± 2.0 | 14.5 ± 1.7 | 13.4 ± 1.3# |
10%FS + XRT (+4 wks) | 7.4 ± 1.0 | 16.6 ± 0.6 | 13.0 ± 1.8* | 16.2 ± 1.2# § | 0.1 ± 0.0§§ | 444.0 ± 66.8 | 8.8 ± 1.6 | 10.0 ± 1.2 | 6.8 ± 2.2# |
10%FS + XRT (+6 wks) | 7.7 ± 1.2 | 16.5 ± 0.9 | 15.3 ± 1.7$ | 26.8 ± 7.1# | 0.2 ± 0.0§§ | 264.7 ± 150.7 | 9.0 ± 4.8 | 10.0 ± 2.1 | 11.7 ± 1.8# |